stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Total debt
Halozyme Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $2.1B, up 42.3% from $1.5B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $3.3B. Over the past ten years it has ranged from $49.8M (fiscal 2015) to $2.1B (fiscal 2025) — the current reading is the highest in ten years. Halozyme Therapeutics, Inc. ranks 6th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $2.1B | 42.29% |
| FY2024 | $1.5B | 0.44% |
| FY2023 | $1.5B | (0.45%) |
| FY2022 | $1.5B | 71.80% |
| FY2021 | $876.7M | 120.70% |
| FY2020 | $397.2M | (1.33%) |
| FY2019 | $402.6M | 218.55% |
| FY2018 | $126.4M | (37.54%) |
| FY2017 | $202.4M | (6.59%) |
| FY2016 | $216.6M | 334.69% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $3.3B | 51.41% |
| Jun 2026 | $2.1B | 0.09% |
| Mar 2026 | $2.1B | 0.09% |
| Dec 2025 | $2.1B | 41.82% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $5.6B |
| BMRN BioMarin Pharmaceutical Inc. compare | $4.2B |
| HALO Halozyme Therapeutics, Inc. | $3.3B |
| BBIO BridgeBio Pharma, Inc. compare | $1.9B |
| ASND Ascendis Pharma A/S compare | $523.3M |
| TECH Bio-Techne Corp compare | $200.0M |
| EXEL Exelixis, Inc. compare | $191.0M |
| SMMT Summit Therapeutics PLC compare | $100.0M |
| KYMR Kymera Therapeutics, Inc. compare | $602.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on HALO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement